FDA has accepted and granted priority review for a new supplemental Biologics License Application for Keytruda as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
Lynparza was approved in the European Union as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Scientists at the Wellcome Sanger Institute, EMBL's European Bioinformatics Institute and AstraZeneca combined drug response data with CRISPR genetic screens across hundreds of cancer cell lines to better understand how drugs target cancer cells.
Researchers found that the Fasting Mimicking Diet for breast cancer patients may help make chemotherapy work better and potentially help to shield healthy cells from damage while undergoing chemotherapy treatment.
The FY20 Defense Appropriations Act provides funding to the Department of Defense Pancreatic Cancer Research Program to support a collaborative pancreatic cancer research paradigm that reduces the burden of pancreatic cancer.
The FY20 Defense Appropriations Act provides funding to the Department of Defense Rare Cancers Research Program to support for research of exceptional scientific merit in the area of rare cancers research. The RCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20... […]
Marc Theoret, Julia Beaver, Tamy Kim and Laleh Amiri-Kordestani were named to new positions at FDA.
Markus Müschen was named the inaugural director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital. Müschen will also be appointed Arthur H. and Isabel Bunker Professor of Medicine (hematology) and professor of immunobiology at Yale School of Medicine.
Debra Friedman, E. Bronson Ingram Chair of Pediatric Oncology, was named associate director of community science and health outcomes at Vanderbilt-Ingram Cancer Center.
Janice M. Mehnert, an expert in phase I therapeutics and the treatment of skin malignancies, was named associate director for clinical research at NYU Langone Health's Perlmutter Cancer Center.
